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Figure 1.  Mean (±S.D.) plasma gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) 
concentrations in negative control and acetaminophen-treated horses on 7 and 1 days before 
treatment; on treatment days 1, 2, 5, 8, 12, 15, 19, 22, 26 and 30; and 3 and 7 days after treatment 
ceased. There were no differences between treated and untreated horses (P>0.05), and all values 
were within the normal range for this laboratory.  
 
Figure 2. Mean (±S.D.) plasma gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) concentrations 
in negative control and acetaminophen-treated horses on 7 and 1 days before treatment; on treatment days 1, 2, 5, 8, 
12, 15, 19, 22, 26 and 30; and 3 and 7 days after treatment ceased. There were no differences between treated and 
untreated horses (P>0.05), and all values were within the normal range for this laboratory.  
 
At no time before, during, or after acetaminophen administration did these horses have 
elevations of liver or renal indices, nor did the initial indices change throughout the experiment. 
There was no apparent effect of acetaminophen administration on horses compared to the negative 
controls. Selected blood indices are graphed in figures 1-3. 
The use of acetaminophen (paracetamol outside the USA) has remained rare in equine 
practice. West et al. (2011) reported the use of acetaminophen in a badly foundered obese Welsh 
gelding which had become poorly-responsive to conventional non-steroidal anti-inflammatory drugs 
(NSAIDs). Foreman et al. (2016) showed acetaminophen efficacy in a reversible model of equine 
foot lameness. However, there remain no refereed blinded controlled documentations of 
acetaminophen toxicity in horses. The objective was to test the hypothesis that oral acetaminophen 
administered at a dosage 25% higher than that sometimes used clinically in horses would result in 
measurable hepatic toxicity as seen in humans and other species. 
 
All materials and methods used for this study were performed under the approval and authority 
of the University of Illinois Institutional Animal Care and Use Committee (Protocol #17107).  
Subjects: Nine healthy adult horses (3 WB, 3 STB or STB-X, 1 TB, 1 QH, 1 Arabian; age mean 
14.4±4.4, median 14, range 5-21 years; 2 geldings, 7 mares; mean wt 509±114 kg) were assigned 
randomly to negative control (n=3) or acetaminophen-treatment (n=6) groups. Complete physical, 
hematological, serum biochemical, and lameness examinations were performed to ensure that 
each subject was normal before drug was administered. Subjects were negative for equine 
infectious anemia using agar gel immunodiffusion. A minimum of 7 days of stall rest acclimatization 
were allowed after admission and before any trials were begun.  
Six horses were administered generic acetaminophen (Wal-Mart brand “Equate” caplets or 
tablets) orally in a paste at a dosage of 25 mg/kg twice daily for 30 days. Horses were weighed 
twice weekly and daily drug doses were adjusted to changes in body weight the day following new 
weights. As negative controls, 3 horses received no medication but received the same syrup used 
to make the acetaminophen paste orally twice daily.  
Blood samples were analyzed the same day for complete blood counts and plasma 
biochemistry concentrations including hepatic and renal indices. Repeated measures analysis of 
variance and post hoc Tukey’s test were used to identify differences between treatment groups at a 
significance level of P<0.05. 
 
The analgesic effects of acetaminophen (N-acetyl-p-aminophenol) are thought to be mediated via 
serotonin and cannabinoid pathways. Acetaminophen is well-absorbed (91%) from the small intestine in 
horses but more poorly in dogs (45%) (Neirinckx et al. 2010). It is metabolized via hepatic 
glucuronidation in horses but there are no pharmacodynamic data and, until now, no toxicity data in 
horses. The more commonly-used non-steroidal anti-inflammatory drugs (NSAIDs) work by inhibiting one 
or both of the isoenzymes of cyclooxygenase (COX), but pan-COX inhibitors often result in horses in 
gastric and colonic ulcers and renal disease. If acetaminophen can be shown to be safe and efficacious 
in horses, it might provide an alternative to conventional NSAIDs for horses suffering from NSAID-toxicity 
or requiring adjunctive pain relief. 
 GLDH, AST, Alkaline phosphatase, and GGT are all hepatocellular or biliary-specific enzymes 
which are used as determinants of hepatic health in horses. Because all these variables remained 
normal throughout treatment and for 7 days afterward, acetaminophen at this dosage twice daily seems 
to be safe in horses for a prolonged period of time. BUN and creatinine are indicators of renal disease or 
toxicity, and were monitored because clients and veterinarians often ask if acetaminophen has any renal 
toxicity; they are so used to NSAID-induced renal disease that they expect it with acetaminophen as 
well. However, we saw no evidence of renal effects of acetaminophen in these horses. Plasma total 
protein is a simple indicator of hydration status and was unchanged in this experiment.  
FDA-approved New Application for Drug Approval (NADA) studies require considerably more horses 
for safety and tolerance studies, and require euthanasia and necropsy of those horses after chronic drug 
administration. For example, the NADA for FDA approval of an equine dose and label indication for 
ceftiofur sodium (https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProdu 
cts/FOIADrugSummaries/UCM539438.pdf) required the use of considerably more horses, and required 
in some experiments the termination and necropsy of those horses. In that series of experiments, Dr. 
Jonathan Foreman participated in clinical trials studying ceftiofur efficacy against both negative and 
positive controls (Federal Drug Administration 1994). It was not our intent in this current research to 
pursue a NADA-type study. There will never be enough money in the marketplace to justify the high cost 
of doing an NADA study for such an affordable, widely-available generic drug. We simply sought data to 
justify its safety, or non-safety, for chronic use in horses with chronic musculoskeletal pain, at a very 
affordable price. 
Horses remained in VTH LAC Ward 3 stalls throughout the study to control timing, type, and amount 
of hay and grain administered twice daily. Grazing would have caused an unquantifiable amount of 
forage to be eaten by individual horses. Recent work with other drugs in horses (UIUC IACUC #s 14261 
and 16055) has documented the effects of feeding on oral drug bioavailability in horses. Dr. Foreman 
has housed horses in these same stalls for over 90 consecutive days when horses were wearing special 
shoes which can be damaged by pasture turnout exercise, with no adverse effects to the horses from 
being housed inside during that period of time. No adverse effects due to chronic housing were observed 
in these horses; one horse had a stereotypical circling behavior which she had had prior to admission to 
this study. 
It was concluded that this dose, 25% higher than that commonly used in horses with clinical 
lameness, did not cause renal, hepatic, or red blood cell injury to the horses studied in this experiment. 
The slightly lower dosage (20 mg/kg twice daily) used more commonly should be safe for most healthy 
horses for up to 30 days. 
Abstract 
There are no controlled studies of acetaminophen toxicity in horses. The objective was to test 
the hypotheses that oral acetaminophen administered at a dosage 25% higher than that 
sometimes used in horses would result in measurable hepatic toxicity as seen in humans and 
other species. Six healthy adult horses were administered 25 mg/kg acetaminophen powder in 
corn syrup twice daily for 30 days. Three other horses served as negative controls receiving only 
corn syrup. Jugular venous blood samples were obtained on days 7 and 1 before treatment; on 
treatment days 1, 2, 5, 8, 12, 15, 19, 22, 26 and 30; and on days 3 and 7 after treatment ceased.  
Samples were analyzed the same day for complete blood counts and plasma biochemistry 
concentrations including hepatic and renal indices. Repeated measures analysis of variance and 
post hoc Tukey’s test were used to identify differences between treatment groups at a significance 
level of P<0.05. On all sampling days, there were no differences between treated and untreated 
horses (P>0.05), and all measured values were within the normal range for this laboratory.    
It was concluded that acetaminophen at this oral dosage was not toxic in any measurable 
manner to the 6 horses receiving the drug in this way. It is postulated that the use of twice daily 20 
mg/kg orally should be safe for periods less than 30 days in healthy horses. 
 
Figure 3. Mean (±S.D.) plasma blood urea nitrogen (BUN) and creatinine concentrations in negative control and 
acetaminophen-treated horses on 7 and 1 days before treatment; on treatment days 1, 2, 5, 8, 12, 15, 19, 22, 26 and 
30; and 3 and 7 days after treatment ceased. There were no differences between treated and untreated horses 
(P>0.05), and all values were within the normal range for this laboratory.    
